Personal information

Websites & social links

LinkedIn profile

Other IDs

Scopus Author ID: 57198515137
SciProfiles: 3278768

Keywords

hematology, chronic lymphocytic leukemia, cll, richter

Countries

Italy, United States

Biography

Hematologist.
Medicine and surgery degree at Università Cattolica del Sacro Cuore, Rome, under the supervision of Prof.Luca Laurenti, MD.
Hematology residency at University of Florence.
From January 2023 to July 2023 visiting research scholar at Dana-Farber Cancer Institute, in Jennifer Brown (MD, PhD) lab.

Activities

Collapse all

Education and qualifications (3)

Università degli Studi di Firenze Scuole di Specializzazione: Firenze, Toscana, IT

2019-11-01 to 2023-11-08 | Hematology residency
Education
Source: Self-asserted source
Francesca Morelli

Dana-Farber Cancer Institute: Boston, US

2023-01-23 to 2023-07-28 | Research scholar (Medical Oncology)
Education
Source: Self-asserted source
Francesca Morelli

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia: Roma, Lazio, IT

2019-03-06 | Magistral degree in Medicine and Surgery
Education
Source: Self-asserted source
Francesca Morelli

Works (13)

Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience

Cancers
2023-11-26 | Journal article
DOI: 10.3390/cancers15235592
Contributors: Idanna Innocenti; Alberto Fresa; Annamaria Tomasso; Michela Tarnani; Laura De Padua; Giulia Benintende; Raffaella Pasquale; Eugenio Galli; Francesca Morelli; Diana Giannarelli et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

CLL-189 Ibrutinib Treatment and Its Impact on Circulating Immune Cells in Chronic Lymphocytic Leukemia Patients

Clinical Lymphoma, Myeloma and Leukemia
2022 | Journal article
DOI: 10.1016/S2152-2650(22)01334-9
EID:

2-s2.0-85138589173

Part of ISSN: 21522669 21522650
Contributors: Morelli, F.; Rapolla, C.M.; Sanna, A.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia

Therapeutic Advances in Hematology
2022 | Journal article
DOI: 10.1177/20406207221127550
EID:

2-s2.0-85139716490

Part of ISSN: 20406215 20406207
Contributors: Frustaci, A.M.; Del Poeta, G.; Visentin, A.; Sportoletti, P.; Fresa, A.; Vitale, C.; Murru, R.; Chiarenza, A.; Sanna, A.; Mauro, F.R. et al.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: A multicenter Italian study

Blood Advances
2022 | Journal article
DOI: 10.1182/bloodadvances.2022006964
EID:

2-s2.0-85134530672

Part of ISSN: 24739537 24739529
Contributors: Fresa, A.; Autore, F.; Piciocchi, A.; Catania, G.; Visentin, A.; Tomasso, A.; Moretti, M.; Vitale, C.; Chiarenza, A.; Morelli, F. et al.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Blood Advances
2021 | Journal article
DOI: 10.1182/bloodadvances.2021004824
EID:

2-s2.0-85118170308

Part of ISSN: 24739537 24739529
Contributors: Tedeschi, A.; Frustaci, A.M.; Mauro, F.R.; Chiarenza, A.; Coscia, M.; Ciolli, S.; Reda, G.; Laurenti, L.; Varettoni, M.; Murru, R. et al.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia

Hematological Oncology
2021 | Journal article
DOI: 10.1002/hon.2837
EID:

2-s2.0-85100342802

Part of ISSN: 10991069 02780232
Contributors: Fresa, A.; Autore, F.; Innocenti, I.; Piciocchi, A.; Tomasso, A.; Morelli, F.; Sorà, F.; Sica, S.; De Stefano, V.; Laurenti, L.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia

British Journal of Haematology
2020 | Journal article
DOI: 10.1111/bjh.16975
EID:

2-s2.0-85088105366

Part of ISSN: 13652141 00071048
Contributors: Corbingi, A.; Innocenti, I.; Tomasso, A.; Pasquale, R.; Visentin, A.; Varettoni, M.; Flospergher, E.; Autore, F.; Morelli, F.; Trentin, L. et al.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis

Leukemia and Lymphoma
2019 | Journal article
DOI: 10.1080/10428194.2018.1523401
EID:

2-s2.0-85061185189

Part of ISSN: 10292403 10428194
Contributors: Innocenti, I.; Morelli, F.; Autore, F.; Corbingi, A.; Pasquale, R.; Sorà, F.; Pompili, M.; Laurenti, L.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience

Hematological Oncology
2019 | Journal article
DOI: 10.1002/hon.2684
EID:

2-s2.0-85074833477

Part of ISSN: 10991069 02780232
Contributors: Autore, F.; Fresa, A.; Innocenti, I.; Tomasso, A.; Morelli, F.; Corbingi, A.; Sorà, F.; Laurenti, L.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax

Leukemia and Lymphoma
2019 | Journal article
DOI: 10.1080/10428194.2019.1612063
EID:

2-s2.0-85066090213

Part of ISSN: 10292403 10428194
Contributors: Innocenti, I.; Morelli, F.; Autore, F.; Tomasso, A.; Corbingi, A.; Bellesi, S.; Za, T.; De Stefano, V.; Laurenti, L.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience

Hematological Oncology
2019 | Journal article
DOI: 10.1002/hon.2623
EID:

2-s2.0-85066608218

Part of ISSN: 10991069 02780232
Contributors: Autore, F.; Innocenti, I.; Morelli, F.; Sorà, F.; Corbingi, A.; Fianchi, L.; Criscuolo, M.; Pagano, L.; Sica, S.; Laurenti, L.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience

British Journal of Haematology
2019 | Journal article
DOI: 10.1111/bjh.16123
EID:

2-s2.0-85072628454

Part of ISSN: 13652141 00071048
Contributors: Innocenti, I.; Morelli, F.; Autore, F.; Piciocchi, A.; Frustaci, A.; Mauro, F.R.; Schiattone, L.; Trentin, L.; Del Poeta, G.; Reda, G. et al.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier

Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia

Expert Review of Hematology
2017 | Journal article
DOI: 10.1080/17474086.2017.1398642
EID:

2-s2.0-85036646555

Part of ISSN: 17474094 17474086
Contributors: Innocenti, I.; Autore, F.; Pasquale, R.; Morelli, F.; Efremov, D.G.; Laurenti, L.
Source: Self-asserted source
Francesca Morelli via Scopus - Elsevier
How many people are using ORCID?